2-o, 3-o desulfated heparin
Small moleculeexperimental
Clinical trial activity
5 trials · 7 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Apr 1, 2007 (NCT00457951)
Timeline
Indications
Mechanism of action
- Unspecified targetUnclear
unclear
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- 2-o, 3-o desulfated heparin
- odsh
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02164097 | Phase 1 | Jan 1, 2015 | New York Medical College |
| NCT01843634 | Early Phase 1 (Phase 1) | Aug 1, 2013 | Cantex Pharmaceuticals, University of Utah |
| NCT01461915 | Phase 2 | Nov 1, 2011 | Cantex Pharmaceuticals, Mayo Clinic, Translational Drug Development |
| NCT01161641 | Phase 1 | Jul 1, 2010 | Cantex Pharmaceuticals, University of Michigan |
| NCT00457951 | Phase 2 | Apr 1, 2007 | Cantex Pharmaceuticals, Gottfried Wilhelm Leibniz Universität Hannover |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (7)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Cantex Pharmaceuticals | For profit | 4 | 4 | 2 | 2007 |
| Gottfried Wilhelm Leibniz Universität Hannover | Academic/Hospital | 1 | 0 | 1 | 2007 |
| Mayo Clinic | Academic/Hospital | 1 | 0 | 1 | 2011 |
| New York Medical College | Academic/Hospital | 1 | 1 | 1 | 2015 |
| Translational Drug Development | For profit | 1 | 0 | 1 | 2011 |
| University of Michigan | Academic/Hospital | 1 | 0 | 1 | 2010 |
| University of Utah | Academic/Hospital | 1 | 0 | 1 | 2013 |
7 organizations
Page 1 / 1